Moleculin Announces Completion of Enrollment in U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB107)

/PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a growing pipeline, including...

Related Keywords

Houston ,Texas ,United States ,Dublin ,Ireland ,Jenene Thomas ,Walter Klemp ,Twitter ,Exchange Commission ,Eastern Cooperative Oncology Group ,Facebook ,Prnewswire Moleculin Biotech Inc ,Securities Exchange ,Nasdaq ,Company Us Phase ,Connective Tissue Oncology Society Annual Meeting ,Linkedin ,Drug Administration ,Moleculin Biotech Inc ,Fast Track Status ,Orphan Drug Designation ,Chief Executive Officer ,Connective Tissue Oncology Society ,Annual Meeting ,Moleculin Biotech ,Transcription Modulator ,Securities Act ,Securities Exchange Act ,Private Securities Litigation Reform Act ,Nc ,